Review Article

Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer

Table 1

FGFR protein expressions on immunohistochemical analysis and clinical outcomes in GC.

ā€‰Definition of positivityPositive case %Relation to clinicopathological factorsRelation to survivalReference

FGFR1222Scoring system of intensity + extensity29T, N, M, stageWorse[19]

FGFR29502+ or 3+, >50%31T, N, M, stageWorse[22]
222Scoring system of intensity + extensity51T, N, M, stageWorse[19]
136Stronger than normal epithelium31 T, peritoneal Dissemination, diffuse typeWorse[20]
49Stronger than normal epithelium41 Stage
Undifferentiated type
Worse[21]

FGFR3222Scoring system of intensity + extensity64NANA[19]

FGFR4222Scoring system of intensity + extensity score79T, N, M, stageWorse[19]
94 3+, >10%38 NAWorse[23]

T: tumor depth; N: lymph-node metastasis; M: distant metastasis; NA: not assisted.